Status:
RECRUITING
The EMBRACE Study The EMBRACE Study
Lead Sponsor:
University of Aberdeen
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Cardiomyopathy is a condition that affects the heart muscle, whereby it becomes enlarged, thick or rigid. When the heart muscle becomes involved, it affects the pumping action of the heart. This condi...
Detailed Description
There is emerging cellular and experimental evidence that cardiac energetic status is reduced after anthracycline treatment, however, this has not been tested in the human heart. The researchers hypot...
Eligibility Criteria
Inclusion
- A patient who has been diagnosed with breast cancer and has been scheduled for a first cycle of anthracycline therapy.
- Participant who is willing and able to give informed consent for participation in the study.
- Healthy (gender and age matched) volunteers willing to give informed consent for participation in the study.
Exclusion
- Contraindication to magnetic resonance scanning such as an implantable cardiac device.
Key Trial Info
Start Date :
February 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2030
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04467411
Start Date
February 1 2020
End Date
August 30 2030
Last Update
December 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cardiovascular Research Facility
Aberdeen, Aberdeenshire, United Kingdom, AB25 2ZD